eyeforpharma Unveils Industry Advisory Board

Stakeholder Partnership Signals New Chapter for Creative Debate

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

London, UK (PRWEB UK) 10 December 2012

Twelve key figures from the healthcare industry have lent their skills and endorsement to eyeforpharma with the formation of the company’s newly announced Industry Advisory Board. The group includes senior directors, CEOs, payers and leading patient advocates, and will serve to help steer the company’s message on key industry concerns throughout 2013 and beyond.

Craig Sharp, Editor at eyeforpharma recently described the board as “…an opportunity to ensure that the industry’s most popular content and events business is representative not of the issues that impact us now, but the trends that will deliver new business opportunities over the next 5-10 years. The board will also ensure eyeforpharma continues to innovate and use its enormous pool of global relationships to pioneer worthwhile causes (such as the recent Mobile App Competition) with the utmost integrity”

Simon Davies, CEO of Teenage Cancer Trust and Chairman of Cancer 52 said of his appointment:

“I am honoured to be able to join the first eyeforpharma advisory board in my capacity as CEO of Teenage Cancer Trust and Chair of Cancer 52. I was motivated to do so by my shared beliefs that the Pharmaceutical Industry needs help to change and adapt to a new and exciting era.”

“Patients and their representatives will play a far more visible and influential role in the future development of drugs, therapies and treatments. They can help the industry innovate and deliver in a way that will better serve the needs of patients and the health systems that support them. I believe eyeforpharma is an organisation that can play a vital role in enabling and supporting those changes, with patient need at the very heart of its philosophy. I will support and advise them for as long as they deliver that promise.”

Simon Davies joins a Board that includes a veritable “who’s who” of healthcare, with Stephen Whitehead, CEO of the ABPI, Chris Preti, Vice President of Patient Engagement at GlaxoSmithKline and Huw Tippett, Head of Global Sales General Medicine at Novartis all also included. For the full membership as well as the board’s mission statement visit: http://bit.ly/UJGohC.

# # #


Contact

  • Jack Ojari
    jack@eyeforpharma.com
    02073757519
    Email